Impact of Caffeine on Aquatic Ecosystems: Assessing Trophic-Level Biological Responses
- PMID: 40558869
- PMCID: PMC12193926
- DOI: 10.3390/jox15030086
Impact of Caffeine on Aquatic Ecosystems: Assessing Trophic-Level Biological Responses
Abstract
This study evaluates the effects of caffeine (CAF) on the bacteria Aliivibrio fischeri, the microalga Raphidocelis subcapitata, the macrophyte Lemna minor, and the larvae of Chironomus riparius, aiming to understand its environmental impact and contribution to ecological risk assessment. Bioluminescence inhibition in A. fischeri (EC50 = 998.5 mg/L) and growth inhibition in R. subcapitata and L. minor (EC50 = 60.1 mg/L and EC50 = 649.2 mg/L, respectively) were observed. For L. minor, reduced catalase (CAT) activity and non-linear responses in glutathione S-transferases (GSTs) were recorded. No significant changes were observed in proline, malondialdehyde (MDA), and pigment contents. In C. riparius, acute mortality (LC50 = 644.5 mg/L) was observed, and growth was significantly affected after 10 days of CAF exposure (EC50 = 81.62 mg/L for fresh biomass). After 10 days of exposure, there was an increase in CAT activity and thiobarbituric acid reactive substances, with TBARS levels both at concentrations ≥82.64 mg/L, and a decrease in GSTs (92.18 mg/L) and acetylcholinesterase (AChE) (≤62.09 mg/L) activities of C. riparius. The results show that CAF exposure affects organisms' metabolic and physiological functions, with varying sensitivities among species, potentially leading to ecological disturbances in aquatic ecosystems. The hazardous concentration for 5% of species was 4.42 mg/L. Long-term studies are necessary to understand the risk of caffeine under more realistic scenarios.
Keywords: ecotoxicology; emerging contaminant; freshwater ecosystems; individual and sub-individual responses; species sensitivity distribution.
Conflict of interest statement
The authors declare no competing interests.
Figures





Similar articles
-
Sertindole for schizophrenia.Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2. Cochrane Database Syst Rev. 2005. PMID: 16034864 Free PMC article.
-
Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review.Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD001901. doi: 10.1002/14651858.CD001901.pub2. Cochrane Database Syst Rev. 2012. PMID: 22972056 Free PMC article.
-
Aspirin (single dose) for perineal pain in the early postpartum period.Cochrane Database Syst Rev. 2017 Feb 9;2(2):CD012129. doi: 10.1002/14651858.CD012129.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 Jul 24;7:CD012129. doi: 10.1002/14651858.CD012129.pub3. PMID: 28181214 Free PMC article. Updated.
-
Folic acid with or without vitamin B12 for cognition and dementia.Cochrane Database Syst Rev. 2003;(4):CD004514. doi: 10.1002/14651858.CD004514. Cochrane Database Syst Rev. 2003. Update in: Cochrane Database Syst Rev. 2008 Oct 08;(4):CD004514. doi: 10.1002/14651858.CD004514.pub2. PMID: 14584018 Updated.
-
Foetal haemoglobin inducers for reducing blood transfusion in non-transfusion-dependent beta-thalassaemias.Cochrane Database Syst Rev. 2023 Jan 13;1(1):CD013767. doi: 10.1002/14651858.CD013767.pub2. Cochrane Database Syst Rev. 2023. PMID: 36637054 Free PMC article.
References
-
- Sharma V.K., Sharma A., Verma K.K., Gaur P.K., Kaushik R., Abdali B. A comprehensive review on pharmacological potentials of caffeine. J. Appl. Pharm. Sci. Res. 2023;6:16–26. doi: 10.31069/japsr.v6i3.04. - DOI
-
- Hawash H.B., Moneer A.A., Galhoum A.A., Elgarahy A.M., Mohamed W.A., Samy M., El-Seedi H.R., Gaballah M.S., Mubarak M.F., Attia N.F. Occurrence and spatial distribution of pharmaceuticals and personal care products (PPCPs) in the aquatic environment, their characteristics, and adopted legislations. J. Water Process Eng. 2023;52:103490. doi: 10.1016/j.jwpe.2023.103490. - DOI
LinkOut - more resources
Full Text Sources
Miscellaneous